{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:37:36Z","timestamp":1792517856580,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.eclinm.2024.102476","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T23:15:31Z","timestamp":1707520531000},"page":"102476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"special_numbering":"C","title":["Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6117-5328","authenticated-orcid":false,"given":"Raffaella","family":"Greco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Del Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Saccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fermin","family":"Sanchez-Guijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil","family":"Sharrack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Snowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6809-917X","authenticated-orcid":false,"given":"Karin","family":"Tarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"S\u00e1nchez-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7045-1806","authenticated-orcid":false,"given":"Joachim","family":"Burman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Castilla Llorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8385-6861","authenticated-orcid":false,"given":"J\u00f6rg","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Mackensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Muraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ricart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsila","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Farge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5153","key":"10.1016\/j.eclinm.2024.102476_bib1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/bmj.2.5153.645","article-title":"Auto-immune disease. I. Modern immunological concepts","volume":"2","author":"Burnet","year":"1959","journal-title":"Br Med J"},{"issue":"10416","key":"10.1016\/j.eclinm.2024.102476_bib2","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"issue":"7042","key":"10.1016\/j.eclinm.2024.102476_bib3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nature03723","article-title":"Paths to understanding the genetic basis of autoimmune disease","volume":"435","author":"Rioux","year":"2005","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102476_bib4","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0030297","article-title":"A\u00a0proposed classification of the immunological diseases","volume":"3","author":"McGonagle","year":"2006","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102476_bib5","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/s41409-022-01702-w","article-title":"Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"57","author":"Alexander","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102476_bib6","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102476_bib7","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102476_bib8","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American society for transplantation and cellular therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102476_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","volume":"55","author":"Sharrack","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102476_bib10","first-page":"267","article-title":"Fibroblast precursors in normal and irradiated mouse hematopoietic organs","volume":"4","author":"Friedenstein","year":"1976","journal-title":"Exp Hematol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102476_bib11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102476_bib12","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jcyt.2013.02.010","article-title":"Therapy MSCCotISfC. Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal","volume":"15","author":"Krampera","year":"2013","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102476_bib13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1089\/scd.2018.0132","article-title":"Human Wharton's Jelly Mesenchymal Stem cells show unique gene expression compared with bone marrow mesenchymal stem cells using single-cell RNA-sequencing","volume":"28","author":"Barrett","year":"2019","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.eclinm.2024.102476_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.918565","article-title":"Optimization of Mesenchymal Stromal Cell (MSC) manufacturing processes for a better therapeutic outcome","volume":"13","author":"Fernandez-Santos","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102476_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/stem.3077","article-title":"Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells","volume":"38","author":"Menard","year":"2020","journal-title":"Stem Cells"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102476_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jcyt.2015.11.008","article-title":"International society for\u00a0cellular therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials","volume":"18","author":"Galipeau","year":"2016","journal-title":"Cytotherapy"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102476_bib17","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1093\/brain\/awaa333","article-title":"Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis","volume":"143","author":"Petrou","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.eclinm.2024.102476_bib18","series-title":"Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases","author":"Burt","year":"2021"},{"key":"10.1016\/j.eclinm.2024.102476_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.100249","article-title":"Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis","volume":"19","author":"Thompson","year":"2020","journal-title":"eClinicalMedicine"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102476_bib20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/DCR.0000000000002325","article-title":"Follow-up study to evaluate the long-term safety and efficacy of darvadstrocel (Mesenchymal Stem Cell Treatment) in patients with perianal fistulizing crohn's disease: ADMIRE-CD phase 3 randomized controlled trial","volume":"65","author":"Garcia-Olmo","year":"2022","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.eclinm.2024.102476_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7061408","article-title":"Prognostic factors for clinical response in systemic lupus erythematosus patients treated by allogeneic mesenchymal stem cells","volume":"2019","author":"Wen","year":"2019","journal-title":"Stem Cells Int"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102476_bib22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/stcltm\/szad010","article-title":"Regulatory B cells contribute to the clinical response after bone marrow-derived mesenchymal stromal cell infusion in patients with systemic sclerosis","volume":"12","author":"Loisel","year":"2023","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102476_bib23","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1016\/S2665-9913(21)00326-X","article-title":"Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1\/2 study","volume":"4","author":"Farge","year":"2022","journal-title":"Lancet Rheumatology"},{"key":"10.1016\/j.eclinm.2024.102476_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-230X-12-143","article-title":"A\u00a0possible involvement of Nrf2-mediated heme oxygenase-1 up-regulation in protective effect of the proton pump inhibitor pantoprazole against indomethacin-induced gastric damage in rats","volume":"12","author":"Lee","year":"2012","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102476_bib25","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1053\/j.gastro.2019.01.025","article-title":"Correction of defective T-regulatory cells from patients with crohn's disease by ex\u00a0vivo ligation of retinoic acid receptor-alpha","volume":"156","author":"Goldberg","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102476_bib26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/art.40737","article-title":"Adoptive Treg cell therapy in a patient with systemic lupus erythematosus","volume":"71","author":"Dall'Era","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102476_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40259-020-00462-7","article-title":"Administration of CD4(+)CD25(high)CD127(-)FoxP3(+) regulatory T cells for relapsing-remitting multiple sclerosis: a phase 1 study","volume":"35","author":"Chwojnicki","year":"2021","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102476_bib28","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jaci.2022.08.003","article-title":"New insights in systemic lupus erythematosus: from regulatory T cells to CAR-T-cell strategies","volume":"150","author":"Doglio","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"21","key":"10.1016\/j.eclinm.2024.102476_bib29","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.3390\/cells11213346","article-title":"Cellular-based therapies in systemic sclerosis: from hematopoietic stem cell transplant to innovative approaches","volume":"11","author":"Xue","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.eclinm.2024.102476_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1075813","article-title":"The emerging role of regulatory cell-based therapy in autoimmune disease","volume":"13","author":"Ghobadinezhad","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.eclinm.2024.102476_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.973813","article-title":"Boosting regulatory T cell function for the treatment of autoimmune diseases - that's only half the battle","volume":"13","author":"Schloder","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102476_bib32","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"10379","key":"10.1016\/j.eclinm.2024.102476_bib33","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"Muller","year":"2023","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.eclinm.2024.102476_bib34","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102476_bib35","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102476_bib36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102476_bib37","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102476_bib38","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41409-023-01958-w","article-title":"Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy","volume":"58","author":"Yakoub-Agha","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102476_bib39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102476_bib40","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102476_bib41","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41409-021-01326-6","article-title":"Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations","volume":"56","author":"Greco","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102476_bib42","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102476_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103612","article-title":"Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases","volume":"28","author":"Felten","year":"2023","journal-title":"Drug Discov Today"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102476_bib44","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102476_bib45","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A\u00a0framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)","volume":"76","author":"van Vollenhoven","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102476_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102476_bib47","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102476_bib48","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102476_bib49","first-page":"447","article-title":"The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus","volume":"86","author":"Hay","year":"1993","journal-title":"Q\u00a0J Med"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102476_bib50","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 Classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102476_bib51","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 11","key":"10.1016\/j.eclinm.2024.102476_bib52","first-page":"S14","volume":"63","author":"Anderson","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102476_bib53","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102476_bib54","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archdermatol.2010.435","article-title":"Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus","volume":"147","author":"Klein","year":"2011","journal-title":"Arch Dermatol"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102476_bib55","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/art.1780401110","article-title":"The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time","volume":"40","author":"Steen","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102476_bib56","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/annrheumdis-2019-215787","article-title":"Revised European Scleroderma trials and research group activity index is the best predictor of short-term severity accrual","volume":"78","author":"Fasano","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102476_bib57","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J\u00a0Scleroderma Relat Disord"},{"issue":"24","key":"10.1016\/j.eclinm.2024.102476_bib58","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102476_bib59","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"5 Suppl 101","key":"10.1016\/j.eclinm.2024.102476_bib60","first-page":"S40","article-title":"The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis","volume":"34","author":"van Riel","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102476_bib61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/joim.12524","article-title":"Diagnosis and classification of idiopathic inflammatory myopathies","volume":"280","author":"Lundberg","year":"2016","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.eclinm.2024.102476_bib62","doi-asserted-by":"crossref","first-page":"e3356","DOI":"10.1002\/btpr.3356","article-title":"An updated overview of the application of CAR-T cell therapy in neurological diseases","volume":"39","author":"Shahabifard","year":"2023","journal-title":"Biotechnol Prog"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102476_bib63","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102476_bib64","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102476_bib65","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102476_bib66","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2217\/cer-2020-0267","article-title":"Efficacy classification of modern therapies in multiple sclerosis","volume":"10","author":"Samjoo","year":"2021","journal-title":"J\u00a0Comp Eff Res"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102476_bib67","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102476_bib68","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102476_bib69","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ncl.2018.01.010","article-title":"Diagnosis of myasthenia gravis","volume":"36","author":"Pasnoor","year":"2018","journal-title":"Neurol Clin"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102476_bib70","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102476_bib71","first-page":"286","article-title":"Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis","volume":"247","author":"Sharshar","year":"2000","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102476_bib72","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102476_bib73","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp.2005.081547","article-title":"A\u00a0modified peripheral neuropathy scale: the overall neuropathy limitations scale","volume":"77","author":"Graham","year":"2006","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"Pt 5","key":"10.1016\/j.eclinm.2024.102476_bib74","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/brain\/awr318","article-title":"Modifying the medical research council grading system through rasch analyses","volume":"135","author":"Vanhoutte","year":"2012","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102476_bib75","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/jnnp.72.5.596","article-title":"Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies","volume":"72","author":"Merkies","year":"2002","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102476_bib76","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ecco-jcc\/jjac144","article-title":"Darvadstrocel for complex perianal fistulas in Japanese adults with crohn's disease: a phase 3 study","volume":"17","author":"Furukawa","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.eclinm.2024.102476_bib77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13287-015-0271-2","article-title":"Biodistribution, migration and homing of systemically applied mesenchymal stem\/stromal cells","volume":"7","author":"Leibacher","year":"2016","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102476_bib78","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood-2009-05-219907","article-title":"Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation","volume":"115","author":"Tarte","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102476_bib79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtct.2022.10.004","article-title":"Successful generation of CD19 chimeric antigen receptor T cells from patients with advanced systemic lupus erythematosus","volume":"29","author":"Kretschmann","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"23","key":"10.1016\/j.eclinm.2024.102476_bib80","first-page":"373","volume":"S0007-4551","author":"Bonnin At","year":"2023","journal-title":"Bull Cancer"},{"key":"10.1016\/j.eclinm.2024.102476_bib81","series-title":"The EBMT\/EHA CAR-T cell handbook","author":"Kroger","year":"2022"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102476_bib82","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.eclinm.2024.102476_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.08.023","article-title":"Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy","volume":"31","author":"Nunez","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102476_bib84","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/bloodadvances.2022007806","article-title":"Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy","volume":"7","author":"Reimann","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102476_bib85","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41409-021-01277-y","article-title":"New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis","volume":"56","author":"Burt","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.eclinm.2024.102476_bib86","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J\u00a0Neuroinflammation"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024000555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024000555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:35:52Z","timestamp":1781642152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024000555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":86,"alternative-id":["S2589537024000555"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102476","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102476"}}